OTC · Financial Statements

Eurofins Scientific SE (ERFSF) Financial Statements

$81.74 OTC: ERFSF Market Cap $14.14B

Eurofins Scientific SE most recently reported annual revenue of $7.3B, net profit of $475.0M. Revenue grew at an average annual rate of 6.0% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Eurofins Scientific SE: Revenue rose from $2.5B in 2016 to $7.3B in 2025, a change of +187.5% over 9 years; net profit was positive in all 10 reported years; operating margin was broadly flat at about 11.2%; the most recent year shows net profit of $475.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$2.5B$3.0B$3.8B$4.6B$5.4B$6.7B$6.7B$6.5B$7.0B$7.3B
Operating Expenses$2.3B$2.7B$3.4B$4.1B$4.1B$5.5B$5.9B$5.3B$6.2B$6.5B
Operating Profit$282.0M$287.0M$338.0M$422.0M$1.3B$1.3B$783.0M$1.2B$726.0M$818.0M
Operating Margin11.1%9.7%8.9%9.3%23.8%18.8%11.7%19.0%10.4%11.2%
Other Income$-39.0M$-37.0M$-47.0M$-150.0M$694.0M$-204.0M$-3.0M$-816.0M$-172.0M$-164.0M
Interest$69.0M$55.0M$66.0M$98.0M$104.0M$173.0M$106.0M$129.0M$151.0M$166.0M
Depreciation$173.0M$216.0M$302.0M$496.0M$370.0M$390.0M$444.0M$664.0M$469.0M$723.0M
Profit Before Tax$243.0M$250.0M$290.0M$272.0M$694.0M$1.1B$780.0M$423.0M$555.0M$654.0M
Tax$26.8M$12.5M$22.9M$28.1M$22.2M$25.9M$22.3M$27.3M$26.9M$27.7M
Net Profit$174.0M$217.0M$224.0M$195.0M$539.0M$783.0M$610.0M$310.0M$406.0M$475.0M
EPS$0.82$1.00$1.22$1.05$2.75$3.90$3.07$1.57$2.09$2.54
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricJun '20Dec '20Jun '21Dec '21Jun '22Dec '22Jun '23Dec '23Jun '24Dec '24Jun '25Dec '25
Revenue$2.3B$3.1B$3.3B$3.4B$3.4B$3.3B$3.2B$3.3B$3.4B$3.5B$3.6B$3.7B
Operating Expenses$2.1B$2.5B$2.5B$2.9B$2.9B$3.0B$2.9B$2.3B$2.7B$2.8B$2.9B$3.6B
Operating Profit$203.0M$602.0M$730.0M$540.0M$493.0M$290.0M$267.0M$972.0M$699.0M$734.0M$754.0M$38.0M
Operating Margin8.8%19.3%22.3%15.7%14.4%8.8%8.3%29.4%20.4%20.8%20.9%1.0%
Interest$51.0M$59.0M$148.0M$58.0M$72.0M$67.0M$55.0M$74.0M$84.0M$67.0M$71.0M$95.0M
Profit Before Tax$150.0M$543.0M$577.0M$478.0M$423.0M$356.0M$219.0M$204.0M$301.0M$254.0M$346.0M$308.0M
Tax$37.3M$18.0M$28.2M$23.2M$27.4M$16.4M$31.4M$22.9M$27.1M$26.7M$28.8M$26.4M
Net Profit$95.0M$445.0M$416.0M$367.0M$310.0M$301.0M$152.0M$159.0M$221.0M$186.0M$247.0M$228.0M
EPS$0.50$2.26$2.07$1.83$1.55$1.52$0.76$0.67$1.00$1.09$1.16$1.23

Over the 10 years reported for Eurofins Scientific SE, borrowings increased from $1.4B in 2016 to $4.4B in 2025, cash stood at $791.0M in the latest year, shareholders' equity was $2.0M, current assets covered current liabilities 1.09 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$4.1B$5.8B$7.2B$7.8B$8.6B$9.3B$10.1B$10.9B$10.9B$11.0B
Current Assets$1.6B$1.8B$1.7B$1.6B$2.5B$2.3B$2.3B$3.1B$2.5B$2.7B
Cash$826.0M$820.0M$506.0M$297.0M$912.0M$515.0M$487.0M$1.2B$614.0M$791.0M
Inventory$40.0M$52.0M$66.0M$79.0M$157.0M$154.0M$146.0M$139.0M$142.0M$139.0M
Receivables$525.0M$706.0M$865.0M$1.0B$1.2B$1.4B$1.3B$1.4B$1.5B$1.5B
Fixed Assets$507.0M$686.0M$1.0B$1.6B$1.6B$1.8B$2.2B$2.3B$2.6B$2.8B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$-468.0M$-104.0M$22.0M$55.0M$57.0M$82.0M$138.0M$88.0M$117.0M$105.0M
Other Assets$1.6B$2.5B$3.4B$3.6B$3.5B$4.1B$4.5B$4.6B$4.8B$4.7B
Total Liabilities$2.4B$3.4B$4.5B$4.9B$4.9B$4.7B$5.2B$5.8B$5.5B$7.4B
Current Liabilities$710.0M$1.5B$1.5B$1.6B$1.7B$1.9B$1.8B$2.1B$2.1B$2.4B
Borrowings$1.4B$2.2B$3.2B$3.5B$3.2B$2.8B$3.3B$3.9B$3.6B$4.4B
Other Liabilities$989.0M$1.1B$1.3B$1.4B$1.7B$1.9B$1.9B$1.8B$1.9B$3.0B
Equity$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M
Reserves$1.6B$2.4B$2.7B$2.8B$3.7B$4.6B$4.8B$5.1B$5.3B$3.5B

For Eurofins Scientific SE, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $535.0M; free cash flow was positive in 10 of 10 years; financing activities used $1.2B in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$372.0M$405.0M$544.0M$678.0M$1.2B$1.5B$1.1B$1.0B$1.3B$1.3B
Investing Cash Flow$-591.0M$-2.0B$-1.9B$-965.0M$-880.0M$-1.6B$-1.5B$-1.2B$-1.4B$-1.8B
Financing Cash Flow$-91.0M$352.0M$-109.0M$-476.0M$-219.0M$-363.0M$-87.0M$282.0M$-634.0M$-1.2B
Net Cash Flow$35.0M$-10.0M$-321.0M$-200.0M$616.0M$-395.0M$-32.0M$738.0M$-608.0M$323.0M
Free Cash Flow$172.0M$159.0M$179.0M$253.0M$868.0M$990.0M$476.0M$468.0M$791.0M$535.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.70
EV / EBITDA15.08
FCF Yield3.37%
Quick Ratio1.03
Interest Coverage6.86
Return 1Y24.29%
Return 3Y70.35%
Return 5Y-26.96%

Eurofins Scientific SE (ERFSF) financials — frequently asked questions

What is Eurofins Scientific SE's annual revenue?

Eurofins Scientific SE (ERFSF) reported annual revenue of $7.3B in its most recent fiscal year.

What is Eurofins Scientific SE's net profit?

Eurofins Scientific SE (ERFSF) reported net profit of $475.0M in its most recent fiscal year.

What is ERFSF EV/EBITDA?

Eurofins Scientific SE's enterprise value to EBITDA (EV/EBITDA) ratio is 15.08.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
ERFSF Overview ERFSF Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.